Search

Your search keyword '"Matsushima, Hisashi"' showing total 204 results
Start Over Author "Matsushima, Hisashi"
204 results on '"Matsushima, Hisashi"'

4. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

Author

Uemura, Hiroji, Matsushima, Hisashi, Kobayashi, Kazuki, Mizusawa, Hiroya, Nishimatsu, Hiroaki, Fizazi, Karim, Smith, Matthew, Shore, Neal, Tammela, Teuvo, Tabata, Ken-ichi, Matsubara, Nobuaki, Iinuma, Masahiro, Uemura, Hirotsugu, Oya, Mototsugu, Momma, Tetsuo, Kawakita, Mutsushi, Fukasawa, Satoshi, Kobayashi, Tadahiro, Kuss, Iris, Le Berre, Marie-Aude, Snapir, Amir, Sarapohja, Toni, and Suzuki, Kazuhiro

Published
2021
Full Text
View/download PDF

5. Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan.

Author

Taguchi, Tetsuya, Matsushima, Hisashi, Kodama, Sho, Okubo, Naoki, Ito, Tetsuo, Ludwikowska, Maja, Fukumoto, Seiji, and Matsumoto, Toshio

Subjects
OSTEOPOROSIS, BREAST cancer, AROMATASE inhibitors, BONE density, PROPENSITY score matching
Abstract

Hormone therapy with aromatase inhibitors (AIs) for estrogen receptor-dependent breast cancer may expose patients to an increased osteoporosis risk. This study was performed to estimate fracture risk in women with breast cancer to whom AIs were prescribed in Japan. This retrospective study used data from the Japanese Medical Data Vision database. Women with breast cancer prescribed AIs over a 12-month period were identified and matched to women not prescribed AIs using a propensity score. Fracture rates were estimated by a cumulative incidence function and compared using a cause-specific Cox hazard model. The proportion of women undergoing bone density tests was retrieved. For all fractures sites combined, cumulative fracture incidence at 10 years was 0.19 [95%CI: 0.16–0.22] in women prescribed AIs and 0.18 [95%CI: 0.15–0.21] without AIs. AI prescription was not associated with any changes in risk (adjusted hazard ratio: 1.08 [95%CI: 0.99–1.17] p = 0.08). Women prescribed AI more frequently underwent bone density testing (31.9% [95% CI: 31.2%; 32.6%] versus 2.2% [95% CI: 2.0%; 2.4%]). The anticipated association between AI exposure and osteoporotic fracture risk in Japanese women with breast cancer was not seen clearly. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

Author

Uemura, Hiroji, primary, Matsushima, Hisashi, additional, Kobayashi, Kazuki, additional, Mizusawa, Hiroya, additional, Nishimatsu, Hiroaki, additional, Fizazi, Karim, additional, Smith, Matthew, additional, Shore, Neal, additional, Tammela, Teuvo, additional, Tabata, Ken-ichi, additional, Matsubara, Nobuaki, additional, Iinuma, Masahiro, additional, Uemura, Hirotsugu, additional, Oya, Mototsugu, additional, Momma, Tetsuo, additional, Kawakita, Mutsushi, additional, Fukasawa, Satoshi, additional, Kobayashi, Tadahiro, additional, Kuss, Iris, additional, Le Berre, Marie-Aude, additional, Snapir, Amir, additional, Sarapohja, Toni, additional, and Suzuki, Kazuhiro, additional

Published
2020
Full Text
View/download PDF

18. OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single‐dose treatment from a phase III, randomized, double‐blind, placebo‐controlled trial (interim analysis)

Author

Yokoyama, Osamu, primary, Honda, Masashi, additional, Yamanishi, Tomonori, additional, Sekiguchi, Yuki, additional, Fujii, Kenji, additional, Nakayama, Takashi, additional, Mogi, Takao, additional, Kitta, Takeya, additional, Ohyama, Chikara, additional, Kambe, Koichi, additional, Tanahashi, Yoshikatsu, additional, Sasagawa, Isoji, additional, Ootani, Mikinobu, additional, Nozawa, Eiyu, additional, Saito, Toshihiko, additional, Manabe, Fumio, additional, Suzuki, Yasutomo, additional, Tomoe, Hikaru, additional, Takahashi, Satoru, additional, Kawata, Nozomu, additional, Matsushima, Hisashi, additional, Kawai, Taketo, additional, Kinjo, Manami, additional, Fukagai, Takashi, additional, Takahashi, Atsuko, additional, Nakajima, Fumio, additional, Sasaki, Haruaki, additional, Okuno, Norihiko, additional, Itoi, Toshiyuki, additional, Ishiura, Yoshiyuki, additional, Mizokami, Atsushi, additional, Matsuta, Yosuke, additional, Sawada, Norifumi, additional, Miwa, Kosei, additional, Otsuka, Atsushi, additional, Funahashi, Yasuhito, additional, Yoshida, Masaki, additional, Tobiume, Motoi, additional, Kawauchi, Akihiro, additional, Okuno, Hiroshi, additional, Nakamura, Terukazu, additional, Ninomiya, Noriko, additional, Matsushita, Chie, additional, Takenaka, Atsushi, additional, Watanabe, Takeshi, additional, Watanabe, Toyohiko, additional, Ishito, Noritaka, additional, Yamamoto, Yasuyo, additional, Ikeda, Hiroshi, additional, Seki, Narihito, additional, Kanegae, Shigehiro, additional, Suyama, Kenichi, additional, Sagiyama, Kazuyuki, additional, Tokuda, Noriaki, additional, Sakai, Hideki, additional, Nishimura, Hiroaki, additional, and Kawahara, Motoshi, additional

Published
2020
Full Text
View/download PDF

26. Detection rate of clinically significant prostate cancer in magnetic resonance imaging and ultrasonography‐fusion transperineal targeted biopsy for lesions with a prostate imaging reporting and data system version 2 score of 3–5

Author

Hakozaki, Yuji, primary, Matsushima, Hisashi, additional, Murata, Taro, additional, Masuda, Tomoko, additional, Hirai, Yoko, additional, Oda, Mai, additional, Kawauchi, Nobuo, additional, Yokoyama, Munehiro, additional, and Kume, Haruki, additional

Published
2018
Full Text
View/download PDF

27. Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR.

Author

Fukumoto, Seiji, Soen, Satoshi, Taguchi, Tetsuya, Ishikawa, Takashi, Matsushima, Hisashi, Terauchi, Masakazu, Horie, Shigeo, Yoneda, Toshiyuki, Sugimoto, Toshitsugu, Matsumoto, Toshio, and Subcommittee for CTIBL in the JSBMR

Subjects
AROMATASE inhibitors, CANCER treatment, OSTEOPOROSIS, BONE fracture prevention, QUALITY of life, FERRANS & Powers Quality of Life Index, ANTIANDROGENS, BONE resorption, TUMORS, BONE density, MEDICAL societies, LONGITUDINAL method, HEALTH planning, DISEASE complications
Abstract

Androgen deprivation therapy and aromatase inhibitors are known to cause a decrease in bone mineral density and an increase in fractures. Patients receiving these treatments have been shown to have a fracture risk equal to or greater than that of patients with osteoporosis with prevalent fractures. This manual was created to prevent fractures in patients with cancer treatment-induced bone loss with high fracture risks who cannot be treated under the current Japanese guideline for the prevention and treatment of osteoporosis. This manual recommends drug treatment for patients with BMD - 2.0 ≤ T score < - 1.5 with the family history of hip fracture or 15% or more 10-year probability of major osteoporotic fractures by FRAX®; or in patients with BMD T score < - 2.0. It is important to verify whether the use of this manual can reduce fractures and improve the quality of life of patients with cancer treatment-induced bone loss by prospective studies. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

29. A prospective study of magnetic resonance imaging and ultrasonography (MRI/US)-fusion targeted biopsy and concurrent systematic transperineal biopsy with the average of 18-cores to detect clinically significant prostate cancer

Author

Hakozaki, Yuji, primary, Matsushima, Hisashi, additional, Kumagai, Jimpei, additional, Murata, Taro, additional, Masuda, Tomoko, additional, Hirai, Yoko, additional, Oda, Mai, additional, Kawauchi, Nobuo, additional, Yokoyama, Munehiro, additional, and Homma, Yukio, additional

Published
2017
Full Text
View/download PDF

30. A Case of Bladder Cancer Arising after Augmentation Cystoplasty Using Ileal Patch for Interstitial Cystitis

Author

Kumagai, Jinpei, Matsushima, Hisashi, Murayama, Shinichiro, Yokoyama, Munehiro, and Homma, Yukio

Subjects
Transitional cell carcinoma, Interstitial cystitis, Bladder, 494.9
Abstract

A 62-year-old man, who was refractory to repeated hydrodistentions for interstitial cystitis, underwent augmentation cystoplasty using ileal patch. Pathological examination revealed no malignancy. Computed tomography (CT) scan showed multiple pelvic and para-aortic lymph-node swellings at 14 months after the operation. CT-guided lymph-nodes biopsies and transurethral bladder biopsies revealed invasive urothelial carcinoma with lymph node metastasis. In patients with symptoms of interstitial cystitis, bladder cancer should be kept in mind despite negative findings of cytology and bladder biopsies.

Published
2014

32. Detection rate of clinically significant prostate cancer in magnetic resonance imaging and ultrasonography‐fusion transperineal targeted biopsy for lesions with a prostate imaging reporting and data system version 2 score of 3–5.

Author

Hakozaki, Yuji, Matsushima, Hisashi, Murata, Taro, Masuda, Tomoko, Hirai, Yoko, Oda, Mai, Kawauchi, Nobuo, Yokoyama, Munehiro, and Kume, Haruki

Subjects
*ENDORECTAL ultrasonography, *MAGNETIC resonance imaging of cancer, *EXOCRINE glands, *PROSTATE cancer, *PROSTATE biopsy, *MAGNETIC resonance imaging, *PROSTATE-specific antigen
Abstract

Objectives: To evaluate the detection rates of clinically significant prostate cancer classified according to the prostate imaging reporting and data system scoring system using magnetic resonance imaging/ultrasound rigid fusion targeted biopsy. Methods: A total of 339 patients underwent transperineal magnetic resonance imaging/ultrasound rigid fusion targeted biopsy in our institution between January 2015 and July 2017. Patients with prostate imaging reporting and data system category 1 or 2 and those with a pre‐biopsy prostate‐specific antigen value of >30 ng/mL were excluded from this study. Finally, 310 patients were recruited. Results: The detection rates of clinically significant prostate cancer with prostate imaging reporting and data system category 3, 4, and 5 were 1.0% (1/98), 35.1% (47/134) and 73.1% (57/78), respectively. The factors affecting the detection of clinically significant prostate cancer with prostate imaging reporting and data system categories 4 and 5 were: (i) prostate imaging reporting and data system category 5; (ii) prostate volume <40 cc; (iii) no previous biopsy; (iv) lesion located in the peripheral zone; and (v) prostate‐specific antigen density >0.35 ng/mL/mL. Conclusions: The detection rate of clinically significant prostate cancer on magnetic resonance imaging/ultrasound rigid fusion targeted biopsy is very low in patients with prostate imaging reporting and data system category 3; therefore, patients with this classification should not undergo targeted biopsy. Prostate‐specific antigen density, prostate volume, locations of suspected cancer and history of biopsy should be considered to predict the detection rate of clinically significant prostate cancer with prostate imaging reporting and data system categories 4 and 5. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

34. A prospective study of magnetic resonance imaging and ultrasonography (MRI/US)-fusion targeted biopsy and concurrent systematic transperineal biopsy with the average of 18-cores to detect clinically significant prostate cancer.

Author

Yuji Hakozaki, Hisashi Matsushima, Jimpei Kumagai, Taro Murata, Tomoko Masuda, Yoko Hirai, Mai Oda, Nobuo Kawauchi, Munehiro Yokoyama, Yukio Homma, Hakozaki, Yuji, Matsushima, Hisashi, Kumagai, Jimpei, Murata, Taro, Masuda, Tomoko, Hirai, Yoko, Oda, Mai, Kawauchi, Nobuo, Yokoyama, Munehiro, and Homma, Yukio

Subjects
DIAGNOSIS, MAGNETIC resonance imaging, ULTRASONIC imaging, PROSTATE cancer, BIOPSY complications
Abstract

Background: This study compared the detection rates for clinically significant prostate cancer (CSPC) between magnetic resonance imaging and ultrasonography (MRI/US)-fusion-targeted biopsy (TB), systematic biopsy (SB) and combination of TB and SB.Methods: This prospective study evaluated simultaneous TB and SB for consecutive patients with suspicious lesions that were detected using pre-biopsy multiparametric MRI. A commercially available real-time virtual sonography system was used to perform the MRI/US-fusion TB with the transperineal technique. The prostate imaging reporting and data system version 2 (PI-RADS v2) was assigned to categorize the suspicious lesions.Results: A total of 177 patients were included in this study. The detection rate for CSPC was higher using SB, compared to TB (57.1% vs 48.0%, p = 0.0886). The detection rate for CSPC was higher using the combination of TB and SB, compared to only SB (63.3% vs 57.1%, p = 0.2324). Multivariate analysis revealed that PIRADS v2 category 4 and an age of <65 years were independent predictors for TB upgrading (vs. the SB result).Conclusions: PI-RADS v2 category 4 and an age of <65 years were predictive factors of upgrading the Gleason score by MRI/US-fusion TB. Thus, MRI/US-fusion TB may be appropriate for patients with those characteristics.Trial Registration: This study was retrospectively registered at the University Hospital Medical Information Network ( UMINID000025911 ) in Jan 30, 2017. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

35. Response to plant cells under microgravity

Author

Sato, Atsushige, Yamada, Yasuyuki, Sato, Fumihiko, Matsushima, Hisashi, and Takeda, Emi

Subjects
transferase, gene manifestation, 脱分化, methionine labeling, 転移酵素, 電気泳動, 遺伝子発現, biochemical analysis, 分化, タバコ, 生合成, メチオニン標識, plant cell, fine structure, 微小重力, 植物細胞, Nicotiana tabacum, dedifferentiation, differentiation, medium, microgravity, 生化学的分析, enzyme activity, 培地, 微細構造, 酵素活性, 培養細胞, electrophoresis, cultured cell, biosynthesis
Abstract

重力場における植物細胞の応答を調べる目的で微小重力下における植物細胞の成長ならびに分化を調べた。今回特に飛行実験用に培養容器を準備したが問題なく使用できることが確認できた。一方、短期間の培養ではあるが、異なる細胞、培地、重力場(微小重力場、1G)いずれの組み合せにおいても植物細胞は生育、分化することが認められた。しかし微小重力場で培養した試料、特にカルス増殖培地に置床した茎切片において地上対照区より顕著な生育のバラツキが認められ、また新鮮物重の増加量も微小重力場で培養した試料の方が劣る傾向が認められた。さらに、重小重力場では地上対照区で観測される複数の不定芽の形成は認められなかった。これらの結果は予想されない結果であり、再実験により確認される必要がある。微小重力下ならびに1G下で培養した組織および細胞内の微細構造を観察した結果、分化培地で培養した場合、微小重力場で再分化した茎頂は1G下で分化した茎頂よりもその発達がわるいことを認めた。また、この時の色素体(葉緑体)の発達は1G下の方がよい傾向がみられた。また細胞骨格を形成する微小管の発達も1G下の方が優れている傾向が認められた。一方、脱分化培地においても茎の側芽において微小重力下にあるものの方がより色素体の脱分化が進んでる傾向が認められた。1次ならびに2次代謝に関係する酵素の活性を測定した結果、微小重力下、再分化培地にて培養したカルスにおいてリグニン生合成の律速酵素であるコーヒー酸o-メチル基転移酵素の活性が地上対象区より著しく低いことを認めた。なお、微小重力下と1G下におけるタンパク質合成活性を35S-メチオニンで標識したのち2次元電気泳動により分離し比較したが、顕著な違いを検出することはできなかった。以上の結果は微小重力場が植物細胞の生長、分化に細胞レベルで影響していることを示していたが、微小重力の影響を知るためにはさらなる実験が必要と考えられた。, Plant cells' growth and differentiation under microgravity were investigated for understanding their response in gravitational field. A specially-devised culture vessel for this space flight was confirmed to work satisfactory. Plant cells grew and differentiated with any combination of different cells, medium, and gravitational fields (micro gravitational field and 1 G), although the culturing period was short. However, samples cultured in micro gravitational field, especially stem sections in callus proliferation medium, showed wider growth variation than ground control samples. The increase in fresh weight also tended to be lower in samples cultured in micro gravitational field. Multiple adventitious bud formation in the ground control samples was not observed in the samples in micro gravitational field. Because these results are unexpected, further experiments are necessary to confirm them. Observing the cultured tissues and intracellular fine structure under microgravity and 1 G showed that the shoot apex redifferentiated in micro gravitational field, when cultured in differentiation medium, grew less than that differentiated under 1 G. The growth of plastid (chlorophyll) and microtubule forming cytoskeleton tended to be higher under 1 G. In dedifferentiated medium, the plastid dedifferentiation in stems' lateral buds also tended to be higher under microgravity. Measuring enzyme activities related to primary and secondary metabolism showed remarkably reduced activity of caffeic acid o-transmethylase, a rate-limiting enzyme of lignin biosynthesis, in a callus cultured in redifferentiated medium under microgravity, compared with that of the ground control samples. In addition, protein synthesis activities under microgravity and 1 G were labeled with S-35-methionine, separated by two-dimensional electrophoresis, and compared. However, it showed no remarkable difference. These results suggest that micro gravitational field has effects on plant cells' growth and differentiation at cellular level. Further experiments are necessary to understand the details of microgravity effects., 資料番号: AA0004115009, レポート番号: NASDA-TMR-940002 V.1

Published
1994

39. CND41, a chloroplast nucleoid protein that regulates plastid development, causes reduced gibberellin content and dwarfism in tobacco

Author

Nakano, Takeshi, primary, Nagata, Noriko, additional, Kimura, Takuma, additional, Sekimoto, Masayo, additional, Kawaide, Hiroshi, additional, Murakami, Shinya, additional, Kaneko, Yasuko, additional, Matsushima, Hisashi, additional, Kamiya, Yuji, additional, Sato, Fumihiko, additional, and Yoshida, Shigeo, additional

Published
2003
Full Text
View/download PDF

41. Treatment of patients with superficial bladder cancer by intravesical instillation of anticancer drugs plus oral chemotherapy following TUR-Bt: A randomized controlled trial

Author

Matsushima, Hisashi, primary, Kawabe, Kazuki, additional, Fujime, Makoto, additional, Kitamura, Tadaichi, additional, Homma, Yukio, additional, Kishi, Hiroichi, additional, Kawamura, Takeshi, additional, Umeda, Takashi, additional, Ohishi, Yukihiko, additional, Murai, Masaru, additional, Kawai, Tsuneo, additional, Yoshida, Hideki, additional, and Fukuda, Takashi, additional

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results